Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perifosine in metastatic renal cell carcinoma
NCT00498966Phase 2Completed
- Sponsor
- COSCIENS Biopharma Inc.
- Start
- Jul 2007
- Primary completion
- Jul 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of perifosine in renal cell carcinoma (RCC) (2 arms), sponsored by COSCIENS Biopharma Inc. Primary endpoints: Objective Response Rate at 12 weeks and Progression-Free Survival for more than 12 weeks. Started Jul 2007; status: completed.
02
Drugs
perifosine
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00498966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00498966.